All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention Bachem, the most common co-covered peer. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Nitto Avecia
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention Bachem, the most common co-covered peer. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window. At 5, the average consequence score sits below the same-window beat average of 5.9. Nitto Avecia appears in 1 tracked Biotech story from March 24, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 20 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Nitto Avecia. Shared-story counts are live from our verified record — not editorial picks.
Codexis (CDXS) has maintained steady analyst sentiment following a strong Q4 2025 performance that exceeded revenue and earnings expectations. The company’s strategic pivot toward its ECO Synthesis platform for RNA manufacturing is gaining commercial traction, supported by a 2026 revenue target of $72M–$76M.